Live feed07:30:00·451dPRReleasevia QuantisnowFDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular AtrophyByQuantisnow·Wall Street's wire, on your screen.SRRK· Scholar Rock Holding CorporationHealth Care
